Who owns Merrimack Pharma Inc?
- Ticker: MACK
- CUSIP Number: 590328209
Tip: Access positions for across all investors
Analyze quarterly positions in Merrimack Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Merrimack Pharma stock
Who bought or sold Merrimack Pharma Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Western Standard | 2.2M | $32M | 0% | Mar 2024 |
|
| Newtyn Management | 1.9M | $28M | 0% | Mar 2024 |
|
| ADAR1 Capital Management | 902k | $13M | 64% | Mar 2024 |
|
| BlackRock | 723k | $11M | 5% | Mar 2024 |
|
| Vanguard Group | 621k | $9.2M | 2% | Mar 2024 |
|
| Madison Avenue Partners | 553k | $7.4M | 0% | Dec 2023 |
|
| Dimensional Fund Advisors | 398k | $5.9M | -9% | Mar 2024 |
|
| Sepio Capital | 307k | $4.1M | 0% | Dec 2023 |
|
| Geode Capital Management | 272k | $4.0M | 8% | Mar 2024 |
|
| Wittenberg Investment Management | 210k | $3.1M | 0% | Mar 2024 |
|
| Yakira Capital Management | 121k | $1.8M | 123% | Mar 2024 |
|
| Northern Trust | 118k | $1.7M | 2% | Mar 2024 |
|
| Bank of New York Mellon | 95k | $1.4M | -5% | Mar 2024 |
|
| Susquehanna International | 90k | $1.3M | -72% | Mar 2024 |
|
| Citadel Advisors | 55k | $810k | 60% | Mar 2024 |
|
| Morgan Stanley | 39k | $583k | -58% | Mar 2024 |
|
| Bridgeway Capital Management | 34k | $505k | 0% | Mar 2024 |
|
| Charles Schwab Investment Management | 30k | $438k | 0% | Mar 2024 |
|
| Two Sigma Investments | 20k | $301k | -7% | Mar 2024 |
|
| OTR - Nominee Name for The State Teachers Retirement Board of Ohio | 19k | $280k | 476% | Mar 2024 |
|
| Goldman Sachs Group | 15k | $214k | -59% | Mar 2024 |
|
| Nuveen Asset Management | 14k | $203k | 0% | Mar 2024 |
|
| Rhumbline Advisers | 14k | $200k | -3% | Mar 2024 |
|
| Johnson Investment Counsel | 14k | $199k | 100% | Mar 2024 |
|
| UBS Group | 12k | $184k | -6% | Mar 2024 |
|
| Jpmorgan Chase & Co | 12k | $174k | 74% | Mar 2024 |
|
| Jane Street | 11k | $164k | 100% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 11k | $160k | 100% | Mar 2024 |
|
| Sherbrooke Park Advisers | 10k | $148k | 100% | Mar 2024 |
|
| Aristides Capital | 10k | $148k | 100% | Mar 2024 |
|
| FMR | 8.3k | $122k | -11% | Mar 2024 |
|
| Barclays | 7.3k | $108k | -49% | Mar 2024 |
|
| MetLife Investment Advisors | 5.6k | $75k | 0% | Dec 2023 |
|
| American International | 5.2k | $70k | 0% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 5.1k | $75k | 67% | Mar 2024 |
|
| Bank of America Corporation | 4.0k | $59k | -68% | Mar 2024 |
|
| Wells Fargo & Company | 3.2k | $48k | 15% | Mar 2024 |
|
| Lazard Asset Management | 2.8k | $37k | -9% | Dec 2023 |
|
| Citigroup | 2.0k | $29k | 24% | Mar 2024 |
|
| Goss Wealth Management | 1.4k | $21k | 0% | Mar 2024 |
|
| New York State Common Retirement Fund | 1.3k | $19k | 0% | Mar 2024 |
|
| Russell Investments | 1.1k | $16k | 4% | Mar 2024 |
|
| California State Teachers Retirement System | 1.1k | $16k | -54% | Mar 2024 |
|
| Legal & General Group | 980.00 | $15k | -24% | Mar 2024 |
|
| Summit Investment Advisors | 865.00 | $13k | 0% | Mar 2024 |
|
| Metropolitan Life Insurance Company | 581.00 | $7.8k | 0% | Dec 2023 |
|
| Brian McDonald | 500.00 | $7.4k | 0% | Mar 2024 |
|
| Royal Bank of Canada | 435.00 | $6.9k | -88% | Mar 2024 |
|
| Deutsche Bank Aktiengesellschaft | 383.00 | $5.7k | -61% | Mar 2024 |
|
| Amalgamated Bank | 353.00 | $5.0k | -76% | Mar 2024 |
|
| Sandy Spring Bank | 300.00 | $4.4k | 0% | Mar 2024 |
|
| Tower Research Capital | 280.00 | $4.1k | -76% | Mar 2024 |
|
| Rise Advisors | 272.00 | $4.0k | 0% | Mar 2024 |
|
| Cornerstone Planning Group | 231.00 | $3.5k | 100% | Mar 2024 |
|
| Pnc Financial Services | 165.00 | $2.4k | 1962% | Mar 2024 |
|
| TSFG | 160.00 | $2.0k | 0% | Mar 2024 |
|
| Covestor | 106.00 | $2.0k | 0% | Mar 2024 |
|
| Federated Investors | 85.00 | $1.1k | -3% | Dec 2023 |
|
| POM Investment Strategies | 69.00 | $1.0k | 100% | Mar 2024 |
|
| Horrell Capital Management | 50.00 | $1.0k | 0% | Mar 2024 |
|
| Armstrong Advisory Group | 45.00 | $603.999000 | 0% | Mar 2024 |
|
| Capital Advisors | 28.00 | $0 | 100% | Mar 2024 |
|
| NISA Investment Advisors | 15.00 | $222.000000 | 0% | Mar 2024 |
|
| CWM | 5.00 | $0 | 100% | Mar 2024 |
|
| GAMMA Investing | 2.00 | $30.000000 | 0% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 2.00 | $29.000000 | 100% | Mar 2024 |
|
Who sold out of Merrimack Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Sio Capital Management | Sep 2023 | 289k | $3.6M |
| Indaba Capital Management | Dec 2023 | 224k | $3.0M |
| Caption Management | Dec 2023 | 126k | $1.7M |
| Rosalind Advisors | Dec 2023 | 60k | $805k |
| Kennedy Capital Management | Dec 2023 | 46k | $620k |
| Allspring Global Investments Holdings | Dec 2023 | 12k | $159k |
| Group One Trading | Sep 2023 | 4.5k | $56k |
| Dorsey Wright & Associates | Sep 2023 | 1.9k | $24k |
| AJOVista | Dec 2023 | 1.5k | $21k |
| Headlands Technologies | Dec 2023 | 300.00 | $4.0k |